Get the Stockscreener App
1.70
7.10%
-0.13
Brainstorm Cell Therapeutics Inc stock is traded at $1.70, with a volume of 31,323.
It is down -7.10% in the last 24 hours and down -23.77% over the past month.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
See More
Previous Close:
$1.83
Open:
$1.8
24h Volume:
31,323
Relative Volume:
0.31
Market Cap:
$9.92M
Revenue:
-
Net Income/Loss:
$-16.63M
P/E Ratio:
-3.9535
EPS:
-0.43
Net Cash Flow:
$-21.84M
1W Performance:
-6.59%
1M Performance:
-23.77%
6M Performance:
-58.77%
1Y Performance:
-70.49%
1-Day Range:
$1.69
$1.81
1-Week Range:
$1.69
$1.93
52-Week Range:
$1.05
$11.89
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Name
Brainstorm Cell Therapeutics Inc
Sector
Industry
Phone
201-488-0460
Address
1325 AVENUE OF AMERICAS, NEW YORK, NY
Compare BCLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
1.7131 | 9.92M | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.19 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.32 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.70 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.20 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.45 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-21 | Upgrade | Maxim Group | Hold → Buy |
| Nov-17-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-19-16 | Reiterated | Maxim Group | Buy |
| Dec-22-15 | Reiterated | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Latest News
5 Best Stem Cell Companies to Invest In (February 2025) - Securities.io
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation - ACCESS Newswire
Amyotrophic Lateral Sclerosis (ALS) Market Future Prospects, - openPR
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded by StockNews.com to Hold Rating - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces Brainstorm Cell Therapeutics Inc. (BCLI) Investigation - ACCESS Newswire
Brainstorm Cell Therapeutics Appeals Nasdaq Delisting - MSN
Brainstorm Cell Therapeutics Appeals Nasdaq Delisting By Investing.com - Investing.com Australia
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded to “Hold” at StockNews.com - Defense World
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Brainstorm Cell Therapeutics faces Nasdaq delisting By Investing.com - Investing.com Nigeria
Brainstorm Cell Therapeutics faces Nasdaq delisting - Investing.com
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - GuruFocus.com
StockNews.com Downgrades Brainstorm Cell Therapeutics (NASDAQ:BCLI) to Sell - Defense World
Mesenchymal Stem Cells Market Outlook 2024: Emerging Trends and Regulatory Shifts Shaping the Future - WICZ
Global Stem Cell Characterization and Analysis Tool Market Size - WICZ
Equities Analysts Offer Predictions for BCLI FY2024 Earnings - Defense World
BCLI: Plans Coming Together for Phase 3b Trial of NurOwn in ALS - Smartkarma
BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS… - MSN
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program - GuruFocus.com
BrainStorm Cell Therapeutics Announces Key Milestones and Strategic Plans for ALS Therapy NurOwn® - Tandav Media
BrainStorm Cell Advances NurOwn ALS Treatment with FDA Special Protocol Assessment and Manufacturing Deal - StockTitan
BrainStorm Issues 2024 Letter to Shareholders - PR Newswire
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update - The Eastern Progress Online
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 - The Eastern Progress Online
Amyotrophic Lateral Sclerosis (ALS) Market: Segmentation - openPR
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Kilgore News Herald
Autologous Cell Therapy Market Expected to Grow at Rapid Rates - openPR
BrainStorm secures patent for exosome technology By Investing.com - Investing.com Nigeria
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - Lelezard
BrainStorm secures patent for exosome technology - Investing.com
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - Marketscreener.com
Gene and Cell Therapies Targeting CNS Disorders Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail
Gene and Cell Therapies Targeting CNS Disorders Treatment - openPR
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Mini - GuruFocus.com
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stem Cell Therapy Market to Reach $19.1 Billion by 2031 | Advanced - openPR
Brainstorm Cell Therapeutics Inc. (BCLI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Expands Stake in Brainstorm Cell Therapeu - GuruFocus.com
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Malaysian Reserve
BrainStorm Cell Reports $2.7M Loss, Plans Phase 3b ALS Trial Despite Low Cash | BCLI Stock News - StockTitan
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
Amyotrophic Lateral Sclerosis Market Opportunities, - openPR
BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership - StockTitan
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
Brainstorm Cell Therapeutics Inc Stock (BCLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Brainstorm Cell Therapeutics Inc Stock (BCLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
| Dagher Ibrahim B. | Chief Medical Officer |
Jul 19 '24 |
Sale |
0.35 |
63,000 |
22,069 |
0 |
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):